甘李药业: 首次公开发行部分限售股上市流通公告

Core Viewpoint - Gann Li Pharmaceutical Co., Ltd. is set to release 4,256,033 shares of restricted stock for public trading on July 25, 2025, following the expiration of the lock-up period for certain shareholders [1][2][6]. Group 1: Stock Listing Details - The stock listing type is an initial public offering (IPO) with a total of 4,256,033 shares being made available for public trading [1]. - The total number of shares listed for circulation is 4,256,033, which represents 0.71% of the company's total share capital [2][8]. - The company received approval from the China Securities Regulatory Commission for the public offering of 40,200,000 shares, which were listed on June 29, 2020 [1][2]. Group 2: Shareholder Commitments - STRONG LINK INTERNATIONAL LIMITED is the shareholder involved in this restricted stock release, and the shares will be unlocked following a written notice from the controlling shareholder, Gan Zhongru [2][6]. - The lock-up period for the shares was initially set for 12 months post-IPO, with an extension contingent upon the controlling shareholder's notification [2][6]. Group 3: Capital Structure Changes - Following the IPO, the company's total share capital increased from 401,100,000 shares to 561,540,000 shares after a cash dividend distribution and stock issuance [3]. - The current total share capital stands at 601,065,290 shares, with 39,666,689 shares under restricted conditions and 561,398,601 shares freely tradable [8]. Group 4: Regulatory Compliance - The company has complied with all relevant regulations and commitments regarding the release of restricted shares, as confirmed by the sponsoring institution [7]. - The release of the restricted shares aligns with the Shanghai Stock Exchange's listing rules and the commitments made during the IPO process [7].